01. Letter from the President

Dear Friends,

I hope you had a good start of the year.

2016 was another busy year for the European Cystic Fibrosis Society, with not only the Basic Science Conference in Italy and the Annual conference in Basel, but a number of special projects and Working Group meetings were held and some selected updates are given below.

Later in this newsletter, you will read about our new website layout, the meetings of the ECFS Registry, CTN and Standards of Care Group. We also have a report from a beneficiary of an ECFS Short-Term Fellowship.

There will be Board elections in 2017 as Marcus Mall and Kevin Southern are ending their terms in office. I would like to encourage you all to consider your own nomination or to nominate an ECFS member you believe would benefit the ECFS community by being actively engaged in the Board. We strongly encourage allied health members to consider standing for a Board position. Please consider how important these elections are for the future of the Society. Further information about the elections is included later in the Newsletter.

Also, I personally will finish my term as President in 2018 and the new President will be elected this year in order to have a smooth transition.

Planning for the 2017 Conference is well underway with all necessary information available on the website. I would like to thank all those who have submitted abstracts and all the speakers who have accepted to contribute to the conference. There was a record number of abstracts submitted this year and we expect a record number of attendees. We have excellent programmes planned and we look forward to your participation.
We have a lot to do over the coming months and I hope you will join us for some of the activities listed below.

Many thanks, as always, to Dr. Henry Ryley for compiling the current references in Cystic Fibrosis contained in this Newsletter

Please contact us if you have news items you would like to have included in future Newsletters or published on our website.

Yours sincerely,

Kris De Boeck
ECFS President
02. Upcoming Events

- ECFS Diagnostic Network Working Group Meeting - 16-18 February 2017, Ljubljana, Slovenia
- 11th European Young Investigators Meeting - 15-17 February 2017, Paris, France
- ECFS 14th Basic Science Conference - 29 March - 01 April 2017, Albufeira, Portugal
- ECFS Board Elections - ! Nomination until March 30th! See more information in point 4 below
- ECFS Board Meeting - 06 June 2017 - Seville, Spain
- 40th European CF Conference - 07-10 June 2017 - Seville, Spain

03. Deadlines

- Nomination ECFS Award - 01 March 2017
- Nomination Gerd Döring Award - 01 March 2017
- Nomination ECFS Elections - 30 March 2017

04. ECFS Board Elections - Call for nominations

The ECFS cordially invites nominations for the following Board positions.

2 Board Positions: Marcus Mall and Kevin Southern will finish their first terms on the Board in 2017.
President Elect: Kris De Boeck will finish her term as President in 2018.

Job Descriptions and person specifics are available for both the President and Board members.
President’s Job Description | Board Member’s Job Description.

Nominations should be sent to the ECFS Executive Director Christine Dubois (christine.dubois@ecfs.eu) by 30 March 2017 together with a motivational statement, confirmation that the candidate has agreed to the nomination, and a curriculum vitae. All nominated candidates must be current members of the ECFS. Information about the nominated candidates will be sent to the membership in early April. Elections will be possible online only via a secured system and open to members of the ECFS (except Corporate members) until the day prior to the Annual General Meeting on 9 June where the results will be announced.
05. ECFS Award - Call for nominations

The ECFS Award is given annually to honour a person who has made an outstanding contribution to our basic understanding of cystic fibrosis or to the treatment or care of patients with cystic fibrosis. The winner of the award will be invited to present a lecture at the Opening Plenary on 7 June 2017 of the annual conference in Seville.

You are cordially invited to nominate a candidate for this award. The **deadline** for proposals is **March 1, 2017**. Please mail your proposal, accompanied by a detailed motivation and curriculum vitae of the candidate to the ECFS Executive Director Christine Dubois (christine.dubois@ecfs.eu).

06. Gerd Döring Award - Call for nominations

The Gerd Döring Award is an initiative of the European Cystic Fibrosis Society and will be given annually to honour an exceptional early career young European scientist. The Award, a monetary donation of 5,000 euro to support research, will be presented at the Opening Plenary of the annual ECFS conference in Seville.

The award will be judged primarily (80%) on a paper published in the previous 3 calendar years (2014-2016) which has made a significant impact on the understanding or treatment of Cystic Fibrosis. Personal motivation and CV will make a 20% contribution to the scoring.

The award is open to PhD students and post-doctoral researchers with up to a maximum of four years’ academic research experience following the completion of their PhD, or be of equivalent professional standing at the date of publication of the paper.

We encourage mentors, supervisors and co-workers of today’s most exceptional early career European scientists to send in nominations for this competition. **Self-nomination is also encouraged.** The **deadline for proposals is March 1, 2017**. Please mail your proposal, accompanied by a detailed motivation, a PDF of the nominated paper and curriculum vitae of the candidate to the ECFS Executive Director Christine Dubois (christine.dubois@ecfs.eu)

07. ECFS Meetings - CTN, Patient Registry, Standards of Care

The ECFS Clinical Trials Network and the ECFS Patient Registry Steering Committees met on 26-27 January in Lisbon for their annual winter meetings. The ECFS Standards of Care Group also organised meetings of some of its subgroups during these days. This was an excellent opportunity to meet across ECFS projects, discuss common subjects and find new and even better opportunities for cooperation.

CTN Steering Committee Lisbon January 2017
08. New Website coming soon!

Our website is undergoing a makeover and will soon be released. We are happy to have new layout that will enable us to more effectively communicate news and inform about the ECFS activities and projects. The new design will provide an easier access to our contents. We will be looking forward to receiving your feedback about the new website and any suggestions you might have to make it better.

09. ECFS Short Term Clinical Fellowship

Here is a short report sent by a recipient of the CF Preceptorship Programme:

My name is Maria Victoria Arenal I am a paediatrician working in a cystic fibrosis centre in Buenos Aires, Argentina; also this year I have started a career as a paediatrician specialising in pulmonology.

In the middle of September the European Cystic Fibrosis Society gave me the opportunity of participating in the Preceptorship programme called: "Managing the care of children and adults with cystic fibrosis". This programme was carried out in London over three weeks; the CF course was held at the Crowne Plaza Hotel for one week and the clinical placement was at the Royal Brompton Hospital - both paediatric and adult centres, for two weeks.

Firstly, the CF course was held over five days, every day we had classes from morning until evening. Each day there was a multidisciplinary approach to all aspects of the cystic fibrosis disease, from management issues - including new therapies and diagnostic methodology to the follow up of CF comorbidities.

Every lecture was given by a professional specialising in the particular subject. Most of the faculty were from different London CF centres, others were from other countries of the European continent. They gave us their experience of many years of work, the specific knowledge of every aspect of the disease and its progress.

The course was a combination of lectures and active participation in workshops, with plenty of time for questions at the end of every session. Course participants were also given a difficult case to discuss and present to the class at the end of the course. From the beginning of the course we had
formed working groups and during the week each group debated, trying to find a resolution to the case before presenting it.

The second part of the course was to go to the Brompton hospital for two full weeks, Monday through Friday as an observer in both the paediatric and adult clinics. My sponsors were Dr. Siobhan Carr in paediatrics and the consultant nurse Dr. Susan Madge within the adult team.

During this time I joined outpatient clinics, often sitting in the room with a patient or in the case of children, with their families as well, and saw the various professionals interacting with patients and each other. Before clinics there were MDT meetings organised to update the team on different aspects of each patient attending the CF clinic that day. I also participated in ward rounds seeing inpatients, how they were followed up, treatments they received and how were handled in an interdisciplinary way. I also attended a radiology round where different patient’s images were discussed.

I would like to explain the importance of a good transition because I think we have to be sure that we do it properly for the patient’s future. I had the opportunity to observe a joint paediatric/adult MDT meeting where every professional discussed each patient prior to their transition from paediatric clinic to adults. They were organised and worked together, I have not seen this kind of transition before, I think it was the best I have ever seen.

Moreover, I also had the opportunity to observe how the paediatric team managed a new CF diagnosis and the different stages they followed according to the Brompton guidelines. I also spent time with one of the clinical nurse specialists in the adult team who was running the adult sweat test clinic.

Finally, I had the chance to spend the day with a physiotherapist, in the morning we discussed the different uses of airway clearance devices and in the afternoon I observed the exercise programmes that are given to patients while they are in hospital.

It was a wonderful and amazing experience for me; I have learnt so much and I think all this information that I have received will be useful to improve the quality of health in our CF population.

Victoria Arenal

10. ECFS Mental Health Working Group

The ECFS Mental Health Working Group has now its dedicated webpage. Just have a look here

If you have an interest in Mental Health and would like to be included in the group’s mailing list or receive further information, please contact the ECFS office at info@ecfs.eu.

11. Job Posting

The CF Centre in Skopje, Macedonia is looking for an adult pulmonologist. Please contact Dr. Oliver Zafirovski through the ECFS office.

12. Current references in CF

Please scroll to next page for full list
Emiralioglu N., Ozturk Z., Yalcin E., Dogru D., Ozelik U., Kiper N.
Long term azithromycin therapy in patients with cystic fibrosis
Turkish Journal of Pediatrics 2016; 58: 34 - 40

Faccione D., Lopez-Ruitti P., Vazquez M., Guerriero L., Lucero C., Gaggiotti P., Ceriana F., Corso A.
Molecular characterization of a clinical Haemophilus parainfluenzae isolate with cefotaxime resistance and decreased susceptibility to fluoroquinolones
Infection Genetics and Evolution 2016; 44: 507 - 509

Flume PA., Clancy JP., Retsch-Bogart GZ., Tullis DE., Bresnik M., Derchak PA., Lewis SA., Ramsey BW.
Continuous alternating inhaled antibiotics for chronic pseudomonas aeruginosa in cystic fibrosis
Journal of Cystic Fibrosis 2016; 15: 809 - 815

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients

Fox DJ., Cooper MD., Speil CA., Roberts ML., Yanik SC., Meech RP., Hargrove TL., Verhulst SJ., Rybak LP., Campbell KCM.
D-Methionine reduces tobramycin-induced ototoxicity without antimicrobial interference in animal models
Journal of Cystic Fibrosis 2016; 15: 518 - 530

Fraser-Pitt D., Mercer D., Lovie E., Robertson J., O’Neill D.
Activity of Cysteamine against the Cystic Fibrosis Pathogen Burkholderia cepacia Complex
Antimicrobial Agents and Chemotherapy 2016; 60: 6200 - 6206

Garcia-Centrares R.
Is Quorum Sensing Interference Viable Alternative to Treat Pseudomonas aeruginosa Infections?
Frontiers in Microbiology 2016; 7: ArtNo: 1454

Gokalsm B., Sesal NC.
Lichen secondary metabolite evernic acid as potential quorum sensing inhibitor against Pseudomonas aeruginosa

Greenberg J., Palmer JB., Chan WW., Correia CE., Whalley D., Shannon P., Sawicki GS.
Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder
Patient Preference and Adherence 2016; 10: 2163 - 2169

Inhalation of tobramycin using simulated cystic fibrosis patient profiles
Pediatric Pulmonology 2016; 51: 1159 - 1167

Israyilova A., Buroni S., Forneris F., Scoffone VC., Shkaliyev NQ., Riccardi G., Chiarelli LR.
Biochemical Characterization of Glutamate Racemase - A New Candidate Drug Target against Burkholderia cepacia Infections
PLoS One 2016; 11: e0167350

Klodzinska SN., Priemel PA., Rades T., Nielsen HM.
Inhalable Antimicrobials for Treatment of Bacterial Biofilm-Associated Sinusitis in Cystic Fibrosis Patients: Challenges and Drug Delivery Approaches
International Journal of Molecular Sciences 2016; 17: 10:1688

In vitro and in vivo evaluation of BMAP-derived peptides for the treatment of cystic fibrosis-related pulmonary infections
Amino Acids 2016; 48: 2253 - 2260

Marshall LJ., Ognejiofor W., Price R., Shur J.
Investigation of the enhanced antimicrobial activity of combination dry powder inhaler formulations of lactoferrin
International Journal of Pharmacaceutics 2016; 514: 399 - 406

Monogoe ML., Pettit RS., Muhlebach M., Cies JJ., Nicolau DP., Kuti JL.
Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation
Antimicrobial Agents and Chemotherapy 2016; 60: 6578 - 6584

Patel K., Goldman JL.
Safety Concerns Surrounding Quinolone Use in Children
Journal of Clinical Pharmacology 2016; 56: 1060 - 1075

Petrone DH., Aitken ML., Ham E., Chung S., Menalía L., Altmann MC., Ayars AG.
Approach to the evaluation of adverse antibiotic reactions in patients with cystic fibrosis
Annals of Allergy Asthma & Immunology 2016; 117: 378 - 381

Plummer A., Wildman M., Gieson T.
Duration of intravenous antibiotic therapy in patients with cystic fibrosis
Cochrane Database of Systematic Reviews 2016: : 9:CD006682

Evaluation of antibacterial and antioxidant mechanisms by usnic acid against methicillin-resistant Staphylococcus aureus
Future Microbiology 2016; 11: 1315 - 1338

Prayle AP., Jain K., Towu DJ., Koch BCP., Knox AJ., Watson A., Smyth AR.
The pharmacokinetics and toxicity of tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison
Journal of Cystic Fibrosis 2016; 15: 510 - 517

Regan KH., Bhatt J.
Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis
Cochrane Database of Systematic Reviews 2016; : 11:CD009876

Riethmuller J., Herrmann G., Graepel-Mainka U., Hellwig D., Heuer HE., Heyder S., Koster H., Kinder B., Kroger K., Paul K., Poplawska K., Melichar VO., Smaczny C., Mellies U.
Sequential Inhalational Tobramycin-Colistin Combination in CF-Patients with Chronic P. Aeruginosa Colonization - an Observational Study
Cellular Physiology and Biochemistry 2016; 39: 1141 - 1151

Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients
Journal of Cystic Fibrosis 2016; 15: 611 - 618

Silveira FP., Abdel-Massih R., Bogdanovich T., Pakstis DL., Routh RL., Moss RB.
Treatment of resistant influenza virus infection in a hospitalized patient with cystic fibrosis with DAS181, a host-directed antiviral Antiviral Therapy 2016; 21: 71 - 74

Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study
Current Medical Research and Opinion 2016; 32: 1789 - 1795

Staubes BA., Metzger NL., Walker SD., Peasah SK.
Evaluation of a Once/Day Tobramycin Regimen to Achieve Target Concentrations in Adult Patients with Cystic Fibrosis
Pharmacotherapy 2016; 36: 623 - 630
In cystic fibrosis: current perspectives

Cystic fibrosis transmembrane conductance regulator modulators

Schmidt BZ., Haaf JB., Leal T., Noel S.
Molecular Therapy

Gruenert DC., Tachikawa K., Chivukula P., Weinberg MS., Saayman SM., Ackley A., Burdach J., Clemson M., pharmacological correctors of the mutant CFTR chloride channel

Development and characterization of synthetic antibodies binding to the cystic fibrosis conductance regulator
MABS 2016; 8: 1167 - 1176

Gentzsch M., Ren HY., Houck SA., Quinney NL., Cholon DSM., Sopha P., Chaudhry IG., Das J., Dokholyan NV., Randell SH., Cyr DM.
Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770
American Journal of Physiology-Lung Cellular and Molecular Physiology 2016; 311: E367 - E374

Lee TWR., Southern KW., Perry LA., Penny-DiNuri JC., Adam AA.
Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease
Cochrane Database of Systematic Reviews 2016; : 6:CD005599

Lopes-Pacheco M.
CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis
Frontiers in Pharmacology 2016; 7: ArNo: 275

McCruie ML., Barnes S., Brodsky JL., Sorscher EJ.
Trafficking and function of the cystic fibrosis transmembrane conductance regulator: a complex network of posttranslational modifications
American Journal of Physiology-Lung Cellular and Molecular Physiology 2016; 311: L719 - L733

Perez-Marques F., Simpson P., Yan K., Quasney MW., Halligan N., Merchant D., Dahmer MK.
Association of polymorphisms in genes of factors involved in regulation of splicing of cystic fibrosis transmembrane conductance regulator mRNA with acute respiratory distress syndrome in children with pneumonia
Critical Care 2016; 20: ArNo: 281

Pesc e E., Gorrieri G., Sirel F., Napolitano F., Carrella D., Ceci E., Tomarli V., Zegarra-Moran O., di Bernardo D., Galietta LJ V.
Evaluation of a systems biology approach to identify pharmacological correctors of the mutant CFTR chloride channel

Long Non-coding RNA BGas Regulates the Cystic Fibrosis Transmembrane Conductance Regulator
Molecular Therapy 2016; 24: 1351 - 1357

Schmidt BZ., Haaf JB., Leal T., Noel S.
Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives
Clinical Pharmacology-advances and Applications 2016; 8: 127 - 140

Sharma N., LaRusch J., Sosnay PR., Gottschalk LB., Lopez AP., Pellicore MJ., Evans T., Davis E., Atalar M., Na CH., Rosson GD., Belchis D., Milewski M., Pandey A., Cutting GR.
A sequence upstream of canonical PDZ-binding motif within CFTR COOH-terminus enhances NHERF1 interaction
American Journal of Physiology-Lung Cellular and Molecular Physiology 2016; 311: L1170 - L1182

Shin YH., Lee SW., Kim M., Choi SY., Cong X., Yu GY., Park K.
Epigenetic regulation of CFTR in salivary gland
Biochemical and Biophysical Research Communications 2016; 481: 31 - 37

Sun Q., Huang JH., Yue YJ., Xu JG., Jian P., Yang DL., Zeng Y., Zhou WL.
Hydrogen Sulfide Facilitates Vaginal Lubrication by Activation of Epithelial ATP-Sensitive K+ Channels and Cystic Fibrosis Transmembrane Conductance Regulator
Journal of Sexual Medicine 2016; 13: 798 - 807

Tazi ME., Dakhilhah DA., Caution K., Gerber MM., Chang SW., Khalil H., Kopp BT., Ahmed AE., Krause K., Davis L., Marsh C., Lovett-Racke AE., Schlesinger LS., Cornet-Boyaka E., Amer AO.
Elevated Mirc1/Mir17-92 cluster expression negatively regulates autophagy and CFTR (cystic fibrosis transmembrane conductance regulator) function in CF macrophages
Autophagy 2016; 12: 2026 - 2037

Telles CJ., Decker SE., Motley WW., Peters AW., Mehr AP., Frizzell RA., Forrest JN.
Functional and molecular identification of a TASK-1 potassium channel regulating chloride secretion through CFTR channels in the shark rectal gland: implications for cystic fibrosis
American Journal of Physiology-Cell Physiology 2016; 311: C884 - C894

CFTR is a tumor suppressor gene in murine and human intestinal cancer
Oncogene 2016; 35: 4191 - 4199

Tu ZW., Chen Q., Zhang JT., Jiang XH., Xia YF., Chan HC.
CFTR is a potential marker for nasopharyngeal carcinoma prognosis and metastasis
Oncotarget 2017; 7: 67955 - 67965

Sw., Khalil H., Kopp BT., Ahmed AE., Krause K., Davis L., Marsh C., Lovett-Racke AE., Schlesinger LS., Cornet-Boyaka E., Amer AO.
Elevated Mirc1/Mir17-92 cluster expression negatively regulates autophagy and CFTR (cystic fibrosis transmembrane conductance regulator) function in CF macrophages
Autophagy 2016; 12: 2026 - 2037

Telles CJ., Decker SE., Motley WW., Peters AW., Mehr AP., Frizzell RA., Forrest JN.
Functional and molecular identification of a TASK-1 potassium channel regulating chloride secretion through CFTR channels in the shark rectal gland: implications for cystic fibrosis
American Journal of Physiology-Cell Physiology 2016; 311: C884 - C894

CFTR is a tumor suppressor gene in murine and human intestinal cancer
Oncogene 2016; 35: 4191 - 4199

Tu ZW., Chen Q., Zhang JT., Jiang XH., Xia YF., Chan HC.
CFTR is a potential marker for nasopharyngeal carcinoma prognosis and metastasis
Oncotarget 2017; 7: 67955 - 67965

Sw., Khalil H., Kopp BT., Ahmed AE., Krause K., Davis L., Marsh C., Lovett-Racke AE., Schlesinger LS., Cornet-Boyaka E., Amer AO.
Elevated Mirc1/Mir17-92 cluster expression negatively regulates autophagy and CFTR (cystic fibrosis transmembrane conductance regulator) function in CF macrophages
Autophagy 2016; 12: 2026 - 2037

Wang G., Linsley R., Norimatsu Y.
External Zn2+ binding to cysteine-substituted cystic fibrosis transmembrane conductance regulator constructs regulates channel gating and curcumin potentiation
FERS Journal 2016; 283: 2458 - 2475

Xia D., Qu JI., Li G., Hongdu BQ., Xu CT., Lin X., Lou YX., He QH., Ma DL., Chen YY.
MARCH2 regulates autophagy by promoting CFTR ubiquitination and degradation and PIK3CA-AKT-MTOR signaling
Autophagy 2016; 12: 1614 - 1630

Zhang Z., Chen J.
Atomic Structure of the Cystic Fibrosis Transmembrane Conductance Regulator
Cell 2016; 167: 1586 -
Clinical
Bioelectrical impedance in young patients with cystic fibrosis: Validation of a specific equation and clinical relevance
Journal of Cystic Fibrosis 2016; 15: 825 - 833
Choi DH., Kim JS., Cutting GR., Searson PC.
Wearable Potentiometric Chloride Sweat Sensor: The Critical Role of the Salt Bridge
Analytical Chemistry 2016; 88: 12241 - 12247
Farahmand F., Tajdini P., Falahi G., Shams S., Mahmoudi S.
Evaluation of Serum Adenosine Deaminase in Cystic Fibrosis Patients in an Iranian Referral Hospital
Iranian Journal of Pediatrics 2016; 26: 3:e2246
Harrington N., Barry PJ., Barry SM.
Dental treatment for people with cystic fibrosis
European Archives of Paediatric Dentistry 2016; 17: 195 - 203
Jelin AC., Sharshiner R., Caughey AB.
Maternal co-morbidities and neonatal outcomes associated with cystic fibrosis
Journal of Maternal-Feetal & Neonatal Medicine 2017; 30: 4 - 7
Ramos KJ., Sack CS., Mitchell KH., Goss CH., Starr JR.
Cystic Fibrosis is Associated with Adverse Neonatal Outcomes in Washington State, 1996-2013
Journal of Pediatrics 2017; 180: 206 - +
Schulz A., Tummler B.
Non-allergic asthma as a CFTR-related disorder
Silva LVRF., Castanos C., Ruiz HH.
Cystic fibrosis in Latin America-Improving the awareness
Journal of Cystic Fibrosis 2016; 15: 791 - 793
Sismanlar T., Aslan AT., Kose M., Pekcan S., Eguz FS., Budakoglu II., Yenicecu I.
Early severe anemia as the first sign of cystic fibrosis
European Journal of Pediatrics 2016; 175: 1157 - 1163
Tagliante L., Trieste L., Solvoll T., Murgia F., Bella S.
Telemonitoring in Cystic Fibrosis: A 4-year Assessment and Simulation for the Next 6 Years
Interactive Journal of Medical Research 2016; 5: 3 – 12
Databases & Registries
Salvatore D., Buzzetti R., Mastella G.
An overview of international literature from cystic fibrosis registries. Part 5: Update 2012-2015 on lung disease
Pediatric Pulmonology 2016; 51: 1251 – 1263
Diabetes
Boudreau V., Coriati A., Hammana L., Ziai S., Desjardins K., Berthiaume Y., Rabasa-Lhoret R.
Variation of glucose tolerance in adult patients with cystic fibrosis: What is the potential contribution of insulin sensitivity?
Journal of Cystic Fibrosis 2016; 15: 839 - 845
Boudreau V., Reynaud Q., Dubois CL., Coriati A., Desjardins K., Durieu I., Rabasa-Lhoret R.
Screening for Cystic Fibrosis-Related Diabetes: Matching Pathophysiology and Addressing Current Challenges
Canadian Journal of Diabetes 2016; 40: 466 - 470
Hunt WK., Helfman BR., McCarty NA., Hansen JM.
Advanced glycation end products are elevated in cystic fibrosis-related diabetes and correlate with worse lung function
Jones GC., Chong ZM., Gilmour J., Matheson C., MacGregor G., Sainsbury CAR.
Patterns and Impact of Hypoglycemia, Hyperglycemia, and Glucose Variability on Inpatients with Insulin-Treated Cystic Fibrosis-Related Diabetes
Diabetes Therapy 2016; 7: 575 - 582
Kim RJ.
Cystic Fibrosis-Related Diabetes in Children: An Update
Pediatric Annals 2016; 45: E321 - E326
Konrad K., Kapellen T., Lilienthal E., Prinz N., Bauer M., Thon A., Rietschel E., Wiemann D., Holl RW.
Does -Cell Autonomy Play a Role in Cystic Fibrosis-Related Diabetes? Analysis Based on the German/Austrian Diabetes Patients Verlaufsdokumentation Registry
Diabetes Care 2016; 39: 1338 - 1344
Liou TG., Jensen JL., Allen SE., Brayshaw SJ., Brown MA., Chatfield B., Koenig J., McDonald C., Packer KA., Peet K., Radford P., Reineke LM., Otuka K., Wagener JS., Young D., Marshall BC.
Improving performance in the detection and management of cystic fibrosis-related diabetes in the Mountain West Cystic Fibrosis Consortium
BMJ Open Diabetes Research & Care 2016; 4: 1:e000183
Sheikh S., Gudipaty L., De Leon DD., Hadjiliddis D., Kubrak C., Rosenfeld NK., Nyirjesy SC., Peleckis AJ., Malik S., Stefanovskii D., Cuchel M., Rubenstein RC., Kelly A., Rickels MR.
Reduced beta-Cell Secretory Capacity in Pancreatic-Insufficient, but Not Pancreatic-Sufficient, Cystic Fibrosis Despite Normal Glucose Tolerance
Diabetes 2017; 66: 134 - 144
Sylvain C., Lamothe L., Berthiaume Y., Rabasa-Lhoret R.
How patients’ representations of cystic fibrosis-related diabetes informs their health behaviours
Psychology & Health 2016; 31: 1129 - 1144
Glucose > 200 mg/dL during Continuous Glucose Monitoring Identifies Adult Patients at Risk for Development of Cystic Fibrosis Related Diabetes
Journal of Diabetes Research 2016; : ArtNo: 1527932
Diagnosis
Collaco JM., Blackman SM., Raragh KS., Corvol H., Rommens JM., Pace RG., Boule PY., McGready J., Sosnay PR., Strug LJ., Knowles MR., Cutting GR.
Sources of Variation in Sweat Chloride Measurements in Cystic Fibrosis
American Journal of Respiratory and Critical Care Medicine 2016; 194: 1375 - 1382
Emiralioglu N., Ozcelik U., Yalcin E., Dogru D., Kiper N.
Diagnosis of cystic fibrosis with chloride meter (Sherwood M926S chloride analyzer (R)) and sweat test analysis system (CF Delta collection system (R)) and sweat test analysis system (CF Delta collection system (R)) compared to the Gibson Cooke method
Turkish Journal of Pediatrics 2016; 58: 27 - 33
Quality of sweat test (ST) based on the proportion of sweat sodium (Na) and sweat chloride (Cl) as diagnostic parameter of cystic fibrosis: are we on the right way? Diagnostic Pathology 2016; 11: ArtNo: 103
Kim J., Farahmand M., Dunn C., Davies Z., Frisbee E., Millia C., Wine JJ.
Evaporimeter and Bubble-Imaging Measures of Sweat Gland Secretion Rates
Mall MA., Stahl M., Graeber SY., Sommerburg O., Kauczor HU., Wielputz MO.
Early detection and sensitive monitoring of CF lung disease: Prospects of improved and safer imaging
Pediatric Pulmonology 2016; 51:
Michl RK., Tabori H., Hentschel J., Beck JF., Mainz JG.
Clinical approach to the diagnosis and treatment of cystic fibrosis and CFTR-related disorders
Stelmach L., Bal-Gieranczcyk K., Szarkowska M.
Atypical cystic fibrosis diagnosed in a 14-year-old boy
Pediatruluia I Medicyna Rodzinna-Paediatrics and Family Medicine 2016; 51: 209 - 213
Tridello G., Menin L., Pintani E., Bergamini G., Assael BM., Melotti P.
Nasal potential difference outcomes support diagnostic decisions in cystic fibrosis
Journal of Cystic Fibrosis 2016; 15: 579 - 582
Wilcanski M., Yaakov Y., Omari I., Zaman M., Martin CR., Cohen-Cymberknoh M., Shosseyov D., Kerem E., Dasilva D., Sheeh S., Uller A., O'Sullivan BP., Friedman S.
Comparison of Nasal Potential Difference and Intestinal Current Measurements as Surrogate Markers for CFTR Function
Journal of Pediatric Gastroenterology and Nutrition 2016; 63: E92 - E97
Epidemiology
Salinas DB., Azen C., Young S., Keens TG., Kharrazi M., Parad RB.
Phenotypes of California CF Newborn Screen-Positive Children with CFTR 5T Allele by TG Repeat Length
Genetic Testing and Molecular Biomarkers 2016; 20: 496 - 503
Sanchez K., de Mendonca E., Sanchez K., de Mendonca E., Matute X., Chaustre I., Vilain E., Coiffier H.
Analysis of the CFTR gene in Venezuelan cystic fibrosis patients, identification of six novel cystic fibrosis-causing genetic variants
Application of Clinical Genetics 2016; 9: 33 - 50
Exercise
Gruet M., Peyre-Tartaruga L., Mely L., Vallier JM.
The 1-Minute Sit-to-Stand Test in Adults With Cystic Fibrosis: Correlations With Cardiopulmonary Exercise Test, 6-Minute Walk Test, and Quadriceps Strength
Respiratory Care 2016; 61: 1620 - 1628
Hatziagorou E., Kampouras A., Avramidou V., Georgopoulou V., Kirvasilis F., Kontouli K., Hebestreit H., Tsanakas J.
Exercise responses are related to structural lung damage in CF pulmonary disease
Pediatric Pulmonology 2016; 51: 914 - 920
Jantzten A., Opoku-Pare M., Bieli C., Ruf K., Hebestreit H., Moeller A.
Perspective on cystic fibrosis and physical activity: Is there a difference compared to healthy individuals?
Pediatric Pulmonology 2016; 51: 1020 - 1030
Reychler G., Debatisse M., Lebecque P., Pieters T., Liistro G., Gohy S.
Variability of gait speed during six minutes walking test in COPD and cystic fibrosis patients
Gait & Posture 2016; 49: 36 - 40
Six minute walk test versus incremental shuttle walk test in cystic fibrosis
Pediatrics International 2016; 58: 887 - 893
Saynor ZL., Barker AR., Oades PJ., Williams CA.
Impaired Pulmonary (V) over dotO(2) Kinetics in Cystic Fibrosis Depend on Exercise Intensity
Medicine and Science in Sports and Exercise 2016; 48: 2090 - 2099
Tomlinson OW., Barker AR., Oades PJ., Williams CA.
Exercise capacity following a percutaneous endoscopic gastrostomy in a young female with cystic fibrosis: a case report
Physiological Reports 2016; 4: 16:e12904
Gastroenterology
Harris J., Sheppard S., Chiu B., Shah A.
Duodenal Atresia and Neonatal Cholestasis in R17H Cystic Fibrosis
Journal of Clinical Neonatology 2016; 5: 112 - 114
Hauser B., De Schepper J., Malfroot A., De Wachter E., De Schutter I., Keymolen K., Vandenplas Y.
Gastric emptying and gastric-oesophageal reflux in children with cystic fibrosis
Journal of Cystic Fibrosis 2016; 15: 540 - 547
Janczyk-Potoczna K., Nowak JK., Madry E., Katulska K., Stetowska-Kubiak S., Moczko J., Lisowska A., Walkowiak J.
Smaller Width of the Pancreatic Duct During Secretin-Enhanced Magnetic Resonance Cholangiopancreatography in Pancreatic-Sufficient Cystic Fibrosis Patients
Pancreas 2016; 45: 1175 - 1178
Kakkoush NO., Pickford R., Jaffe A., Oul CV.
Is there a role for stool metabolomics in cystic fibrosis?
Pediatrics International 2016; 58: 808 - 811
International prospective study of distal intestinal obstruction syndrome in cystic fibrosis: Associated factors and outcome
Journal of Cystic Fibrosis 2016; 15: 531 - 539
Ng SM., Moore HS.
Drug therapies for reducing gastric acidity in people with cystic fibrosis
Cochrane Database of Systematic Reviews 2016; : 8:CD003424
Niccum DE., Billings JL., Dunitz JM., Khoruts A.
Colonoscopic screening shows increased early incidence and progression of adenomas in cystic fibrosis
Journal of Cystic Fibrosis 2016; 15: 548 - 553
Piasecki B., Turska-Malinska R., Matthews-Brzozowska T., Mojs E.
Executive function in pediatric patients with cystic fibrosis, inflammatory bowel disease and in healthy controls
European Review for Medical and Pharmacological Sciences 2016; 20: 4299 - 4304
Pancreatic Elastase-1 Quick Test for rapid assessment of pancreatic status in cystic fibrosis patients
Gene Therapy
Alton EFW., Boyd AC., Davies JC., Gill DR., Griesenbach U., Harrison PT., Henig N., Higgins T., Hyde SC., Innes JA., Korman MSD.
Genetic medicines for CF: Hype versus reality
Pediatric Pulmonology 2016; 51:
Duncan GA., Jung J., Hanes J., Suk JS.
The Mucus Barrier to Inhaled Gene Therapy
Current Opinion in Pulmonary Medicine 2016; 22: 602 - 609
Kim N., Duncan GA., Hanes J., Suk JS.
Barriers to inhaled gene therapy of obstructive lung diseases: A review
Journal of Controlled Release 2016; 240: 465 – 488

General Review
Douli I.
Cystic Fibrosis Papers of the Year 2015
Paediatric Respiratory Reviews 2016; 20:
Massie J., Robinson PJ., Cooper PJ.
The story of cystic fibrosis 1965-2015
Journal of Paediatrics and Child Health 2016; 52: 991 - 994
Willmott RW.
A Historical Perspective of Cystic Fibrosis

Genetics
Celestino-Soper PBS., Simpson E., Brick DT., Lynnes TC., Dhoshy S., Vatta M., Yelej J., Brown C., Baj SC.
Intragenic CFTR Duplication and ST1/2TG Variant in a Patient with Non-Classic Cystic Fibrosis
Scientific Reports 2016; 6: Article No: 38776
Harrison PT., Sanz DJ., Hollywood JA.
Impact of gene editing on the study of cystic fibrosis
Human Genetics 2016; 135: 983 - 992
Heidari S., Hojati Z., Motovaoli-Bashi M.
Screening of Two Neighboring CFTR Mutations in Iranian Infertile Men with Non-Obstructive Azoosperma
Huguet F., Calvez ML., Benz N., Le Hir S., Gaudelus I., Mignen O., Trouve P.
Function and regulation of TRPM7, as well as intracellular magnesium content, are altered in cells expressing Delta F508-CFTR and G551D-CFTR
Cellular and Molecular Life Sciences 2016; 73: 3351 - 3373
Nielsen AO., Qayum S., Bouchelouche PN., Laursen LC., Dahl R., Dahl M.
Risk of asthma in heterozygous carriers for cystic fibrosis: A meta-analysis
Bone Mineral Density and Fat-Soluble Vitamin Status in Adults with Cystic Fibrosis Undergoing Lung Transplantation: A Pilot Study
Canadian Journal of Dietetic Practice and Research 2016; 77: 199 - 202
Marquette M., Haworth CS.
Bone health and disease in cystic fibrosis
Paediatric Respiratory Reviews 2016; 20:

Immunology & Inflammation
Bayes HK., Ritchie ND., Evans TJ.
Interleukin-17 Is Required for Control of Chronic Lung Infection Caused by Pseudomonas aeruginosa
Infection and Immunology 2016; 84: 3507 - 3516
Bruscia EM., Bonfield TL.
Cystic Fibrosis Lung Immunity: The Role of the Macrophage
Journal of Innate Immunity 2016; 8: 550 - 563
Burgess L., Southern KW.
Pneumococcal vaccines for cystic fibrosis
Cochrane Database of Systematic Reviews 2016; : 9:CD008385
Antinflammatory effects of bromodomain and extraterminal domain inhibition in cystic fibrosis lung inflammation
JCI Insight 2016; 1: 11:e87168
Furlan LL., Marson FAL., Ribeiro JD., Bertuzzo CS., Salomao JB., Souza DRS.
IL8 gene as modifier of cystic fibrosis: unraveling the factors which influence clinical variability
Human Genetics 2016; 135: 881 - 894
Guo XQ., Hou YN., Sun F., Yang Z., Li CY.
Dysregulated Chemokine Signaling in Cystic Fibrosis Lung Disease: A Potential Therapeutic Target
Current Drug Targets 2016; 17: 1535 - 1544

Growth & Development
Al-Mendalawi MD.
Growth assessment and risk factors of malnutrition in children with cystic fibrosis
Saudi Medical Journal 2016; 37: 712 - 713
Braun C., Bacchetta J., Reix P.
Insights into cystic fibrosis-related bone disease
Archives de Pediatrie 2016; 23: 857 - 866
Cioca IM., Pop LL., Rogobete AF., Onet DL., Gut-Almajar B., Popa Z., Horhat FG.
Genetic Expression in Cystic Fibrosis Related Bone Disease. An Observational, Transversal, Cross-Sectional Study
Clinical Laboratory 2016; 62: 1725 - 1730
Darrah R., Nelson R., Damato EG., Decker M., Matthews A., Hodges CA.
Growth Deficiency in Cystic Fibrosis Is Observable at Birth and Predictive of Early Pulmonary Function
Biological Research for Nursing 2016; 18: 498 - 504
Delion M., Braux J., Jourdain ML., Guillaume C., Bour C., Gangloff S., Le Pimpec-Barthes F., Sermet-Gaudelus I., Jacquot J., Velard F.
Overexpression of RANKL in osteoblasts: a possible mechanism of susceptibility to bone disease in cystic fibrosis
Journal of Pathology 2016; 240: 50 - 60
Bone Mineral Density and Fat-Soluble Vitamin Status in Adults with Cystic Fibrosis Undergoing Lung Transplantation: A Pilot Study
Canadian Journal of Dietetic Practice and Research 2016; 77: 199 - 202
Marquette M., Haworth CS.
Bone health and disease in cystic fibrosis
Paediatric Respiratory Reviews 2016; 20:
Clinical Immunology 2016; 170: 53

and express IL

J.

M., Ashare A., Gifford AH., Rigby WFC.

Skopelja S., Hamilton BJ., Jone

Journal of

Cystic Fibrosis Lung Disease

Current Concepts and Controversies on Innate Immunity of

A., Hartl D.

Ralhan A., Laval J., Lelis F., Ballbach M., Grund C., Hector A., Hartl D.

Current Concepts and Controversies on Innate Immunity of Cystic Fibrosis Lung Disease

Journal of Innate Immunity 2016; 8: 531 - 540

Skopelja S., Hamilton BJ., Jones JD., Yang ML., Mamula M., Ashare A., Gifford AIL., Rigby WFC.

The role for neutrophil extracellular traps in cystic fibrosis autoimmunity

JCI Insight 2016; 1: 17:e88912

Taylor PR., Bonfield TL., Chmiel JF., Pearlman E.

Neutrophils from F508del cystic fibrosis patients produce IL-17A and express IL-23-dependent IL-17RC

Clinical Immunology 2016; 170: 53 - 60

Thomsen K., Christophersen L., Jensen PO., Bjarnsholt T., Moser C., Huby N.

Anti-Pseudomonas aeruginosa IgY antibodies promote bacterial opsonization and augment the phagocytic activity of polymorphonuclear neutrophils

Human Vaccines & Immunotherapeutics 2016; 12: 1690 - 1699

Chronicke A., Heger N., Antweiler E., Kranich A., Roehmel J., Brandt C., Staab D., Tintelnot K., Schwarz C.

Allergic bronchopulmonary aspergillosis is associated with pet ownership in cystic fibrosis

Pediatric Allergy and Immunology 2016; 27: 597 - 603

Tsuiyahi M., Kalarupalle S., Kumar P., Ghoosal S., Zhang YQ., Lehrmann E., Becker KG., Gorse B, Miswa R.

RPTOR, a novel target of mR-155, elicits a fibrotic phenotype of cystic fibrosis lung epithelium by upregulating CTGF

RNA Biology 2016; 13: 837 - 847

Venceen SF., Greene CM.

Toll-Like Receptors in Cystic Fibrosis: Impact of Dysfunctional microRNA on Innate Immune Responses in the Cystic Fibrosis Lung

Journal of Innate Immunity 2016; 8: 541 - 549


Aspergillus fumigatus components distinguish IgE but not IgG4 profiles between fungal sensitization and allergic bronchopulmonary aspergillosis

Allergy 2016; 71: 1640 – 1643

Liver Disease

Colombo C., Cossignani A., Alicandro G., Zhang WJ., Biffi A., Motta V., Corti F., Setchell KDR.

Long-Term Ursodeoxycholic Acid Therapy Does Not Alter Lithocholic Acid Levels in Patients with Cystic Fibrosis with Associated Liver Disease

Journal of Pediatrics 2016; 177: 59 - +

Srikanth KP., Panighrahi I., Thapa BR., Vaiphei K.

Severe liver dysfunction in an infant with cystic fibrosis a masquerading as metabolic liver disease

Indian Journal of Pathology and Microbiology 2016; 59: 339 - 347

van der Feen C., van der Doef HPJ., van der Ent CK., Houwen RHJ.

Ursodeoxycholic acid treatment is associated with improvement of liver stiffness in cystic fibrosis patients


Microbiology

Agarwal R., Sehgal IS., Dhooria S., Aggarwal AN.

Developments in the diagnosis and treatment of allergic bronchopulmonary aspergillosis


Ahmad S., Tyrrell J., Walton WG., Tripathy A., Redinbo MR., Tarra R.

Short Palate, Lung, and Nasal Epithelial Clone 1 Has Antimicrobial and Antibiofilm Activities against the Burkholderia cepacia Complex

Antimicrobial Agents and Chemotherapy 2016; 60: 6003 - 6012


Sinus surgery postpones chronic Gram-negative lung infection: cohort study of 106 patients with cystic fibrosis

Rhinology 2016; 54: 206 - 213
Albrecht C., Ringshausen F., Ott S., Wagner D., Rademacher J., Schneider M., Welte T., Pletz MW.
Should all adult cystic fibrosis patients with repeated nontuberculous mycobacteria cultures receive specific treatment?
A 10-year case- control study
European Respiratory Journal 2016; 47: 1575 - 1577

Amouroux L., Bador J., Zouak FB., Chapuis A., de Curraize C., Neuwirth C.
Distribution of the species of Achromobacter in a French Cystic Fibrosis Centre and multicolline sequence typing analysis reveal the predominance of A. xylosoxidans and clonal relationships between some clinical and environmental isolates
Journal of Cystic Fibrosis 2016; 15: 486 - 494

Anantharajah A., Mingoet-Leclercq MP., Rambeke F.
Targeting the Type Three Secretion System in Pseudomonas aeruginosa
Trends in Pharmacological Sciences 2016; 37: 734 - 749

Ang JY., Abdel-Haq N., Zhu F., Thabit AK., Nicolau DP., Satlin MJ., van Duin D.
Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis A Population Study
Antimicrobial Agents and Chemotherapy 2016; 60: 5627 - 5630

Staphylococcus aureus Protein A Mediates Interspecies Interactions at the Cell Surface of Pseudomonas aeruginosa
mBio 2016; 7: e00358-16

Bhagirath AY., Li YQ., Somayajula D., Dadashi M., Badr S., Duan KM.
Cystic fibrosis lung environment and Pseudomonas aeruginosa infection
BMC Pulmonary Medicine 2016; 16; ArNo: 174

Boikos C., Joseph L., Martineau C., Papenburg J., Scheifele B.
Inoculation density and nutrient level determine the formation of Pseudomonas aeruginosa Gene Expression Profiles in the Microaerobic Environment
Infection and Immunity 2016; 84: 2995 - 3006

Use of a Multiplex Transcript Method for Analysis of Pseudomonas aeruginosa Gene Expression Profiles in the Cystic Fibrosis Lung
Infection and Immunity 2016; 84: 2995 - 3006

Bhagirath AY., Li YQ., Somayajula D., Dadashi M., Badr S., Duan KM.
Cystic fibrosis lung environment and Pseudomonas aeruginosa infection
BMC Pulmonary Medicine 2016; 16; ArNo: 174

Campbell JL., Kim SE., Chu SY., Johnson JH., Jones LS., Sokolov AG., Niederman MS., Huang YQ., Ray SC.
Monitoring the microbiota composition of the respiratory tract across the CFTR genotype spectrum
Scientific Reports 2016; 6: ArNo: 174

Paediatricians and Children with Bronchopulmonary Aspergillosis: Understanding Differences in Practice
Scientific Reports 2016; 6: ArNo: 174

Cho H., Huang XQ., Piao YL., Kim DE., Lee SY., Yoon EJ., Park SH., Lee K., Jiang CH., Zhan CG.
Molecular modeling and redesign of alginate lyase from Pseudomonas aeruginosa for accelerating CRPA biofilm degradation
Proteins-Structure Function and Bioinformatics 2016; 84: 1875 - 1887

Eradication failure of newly acquired Pseudomonas aeruginosa with cystic fibrosis
Journal of Cystic Fibrosis 2016; 15: 794 - 801

Collaco JM., Rurailgh KS., Appel LJ., Cutting GR.
Respiratory pathogens mediate the association between lung function and temperature in cystic fibrosis
Journal of Cystic Fibrosis 2016; 15: 794 - 801

Coward A., Kenna DTD., Perry C., Martin K., Dousmith M., Turton JF.
Use of nda gene sequence clustering to estimate the prevalence of different Achromobacter species among Cystic Fibrosis patients in the UK

Crull MR., Ramos KJ., Caldwell E., Mayer-Hamblett N., Aitken ML., Goss CH.
Change in Pseudomonas aeruginosa prevalence in cystic fibrosis adults over time
BMC Pulmonary Medicine 2016; 16; ArNo: 176

de Koff EM., de Winter-de Groot KM., Bogaert D.
Development of the respiratory tract microbiota in cystic fibrosis

DePas WH., Starwalt-Lee R., Van Sambeek L., Kumar SR., Gradinaru V., Newman DK.
Exposing the Three-Dimensional Biogeography and Metabolic States of Pathogens in Cystic Fibrosis Sputum via Hydrogel Embedding, Clearing, and RNA Labeling
mBio 2016; 7: e00796-16

Effect of Shear Stress on Pseudomonas aeruginosa Isolated from the Cystic Fibrosis Lung
mBio 2016; 7: e00813-16

Dryahina K., Sovova K., Nemec A., Spanel P.
Dissociation of pulmonary bacterial pathogens in cystic fibrosis by volatile metabolites emitted by their in vitro cultures: Pseudomonas aeruginosa, Staphylococcus aureus, Stenotrophomonas maltophilia and the Burkholderia cepacia complex

Elphick HE., Southern KW.
Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis
Cochrane Database of Systematic Reviews 2016; 11:CD002204

Faraji F., Mahzoumeh M., Ebrahimi A., Fallah F., Teymournajad O., Lajevardi B.
Molecular detection of virulence genes in Pseudomonas aeruginosa isolated from children with Cystic Fibrosis and burn wounds in Iran
Microbial Pathogenesis 2016; 99: 1 - 4

LaS Variant Cystic Fibrosis Isolates Reveal an Adaptable Quorum- Sensing Hierarchy in Pseudomonas aeruginosa
mBio 2016; 7: e01513-16

Flynn JM., Niccum D., Dunitz JM., Hunter RC.
Evidence and Role for Bacterial Mucin Degradation in Cystic Fibrosis Airway Disease
PLoS Pathogens 2016; 12: 8:e1005846

Garnett JP., Kalsi KK., Sobotta M., Bearham J., Carr G., Powell J., Brodlie M., Ward C., Tarran R., Baines DL.
Hyperglycaemia and Pseudomonas aeruginosa acidify cystic fibrosis airway surface liquid by elevating epithelial monocarboxylate transporter 2 dependent lactate-H+ secretion
Scientific Reports 2016; 6: ArNo: 37955

Ghanbari A., Dehgany J., Schwebs T., Musken M., Hausler S., Meyer-Hermann M.
Inoculation density and nutrient level determine the formation of mushroom-shaped structures in Pseudomonas aeruginosa biofilms
Scientific Reports 2016; 6: ArNo: 22907

Gifford AH., Willger SD., Dolben EL., Moulton LA., Dorman DB., Bean H., Hill JE., Hampton TH., Ashare A., Hogan DA.
Use of a Multiplex Transcript Method for Analysis of Pseudomonas aeruginosa Gene Expression Profiles in the Cystic Fibrosis Lung
Infection and Immunity 2016; 84: 2995 - 3006
Pirs AK., Krive U., Simec S., Seme K. Assessment of serology and spirometry and the combination of both to complement microbiological isolation for earlier detection of Pseudomonas aeruginosa infection in children with cystic fibrosis BMC Pulmonary Medicine 2016; 16: ArNo: 161


Rhodes KA., Schweizer HP. Antibiotic resistance in Burkholderia species Drug Resistance Updates 2016; 28: 82 - 90

Rocha GA., Ferreira AG., Lima DF., Leao RS., Carvalho-Assef APD., Folescu TW., Albano RM., Marques EA. Draft genome sequence of Acinetobacter pittii ST643 shared by cystic fibrosis patients Memorias Do Instituto Oswaldo Cruz 2016; 111: 592 - 593


Rogers GB., Narkezwicz MR., Hoffman LR. The CF gastrointestinal microbiome: Structure and clinical impact Pediatric Pulmonology 2016; 51:

Seidler D., Griffin M., Nymon A., Koepken K., Ashare A. Throat Swabs and Sputum Culture as Predictors of P. aeruginosa or S. aureus Lung Colonization in Adult Cystic Fibrosis Patients PLoS One 2016; 11: e0164212


Sherrard LJ., Bell SC., Tunney MM. The role of anerobic bacteria in the cystic fibrosis airway Current Opinion in Pulmonary Medicine 2016; 22: 637 - 643

Sommer LM., Marvig RL., Lujan A., Koza A., Pressler T., Molin S., Johansen HK. Is genotyping of single isolates sufficient for population structure of Pseudomonas aeruginosa in cystic fibrosis airways? BMC Genomics 2016; 17: ArNo:


Talbot NP., Flight WG. Severe Achromobacter xylosidans infection and loss of sputum bacterial diversity in an adult patient with cystic fibrosis Paediatric Respiratory Reviews 2016; 20:


Ziesing S., Suerbaum S., Sedlacek L. Fungal epidemiology and diversity in cystic fibrosis patients over a 5-year period in a national reference center Medical Mycology 2016; 54: 781 – 786

Nutrition


Chesdachai S., Tangpricha V. Treatment of vitamin D deficiency in cystic fibrosis Journal of Steroid Biochemistry and Molecular Biology 2016; 164: 36 - 39

Daitch V., Babich T., Singer P., Leibovici L. Quality of Reporting Nutritional Randomized Controlled Trials in Patients With Cystic Fibrosis Journal of Pediatric Gastroenterology and Nutrition 2016; 63: 265 - 269

Egan H., Mantzios M. Mindfulness and mindful eating: reflections on how individuals with cystic fibrosis may benefit Eating and Weight Disorders-studies On Anorexia Bulimia and Obesity 2016; 21: 511 - 512


Somaraju UR., Solis-Moya A. Pancreatic enzyme replacement therapy for people with cystic fibrosis Cochrane Database of Systematic Reviews 2016; : 11:CD008227

Pancreatic enzyme replacement therapy for people with cystic fibrosis Cochrane Database of Systematic Reviews 2016; : 11:CD008227
Physiotherapy

Krueger-Ziolek S., Schulcke B., Zhao ZQ., Gong B., Nachrig S., Muller-Lisse U., Moeller K.
Multi-layer ventilation inhomogeneity in cystic fibrosis
Respiratory Physiology & Neurobiology 2016; 233: 25 – 32

Psychosocial

Bishay LC., Sawicki GS.
Strategies to optimize treatment adherence in adolescent patients with cystic fibrosis
Adolescent Health Medicine and Therapeutics 2016; 7: 117 - 124

Borschuk AP., Evenhart RS., Eakin MN., Rand-Giovannetti D., Borrelli B., Riekeri KA.
Disease disclosure in individuals with cystic fibrosis: Association with psychosocial and health outcomes

Camidge SL., Duff AJA., Latchford GJ., Etherington C.
When Women with Cystic Fibrosis Become Mothers: Psychosocial Impact and Adjustments
Pulmonary Medicine 2016; : ArtNo: 9458980

Chan DK., McNamara S., Park JS., Vajda J., Gibson RL., Parikh SR.
Sinonasal Quality of Life in Children with Cystic Fibrosis
Jama Otolaryngology-head & Neck Surgery 2016; 142: 743 - 749

Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe
European Journal of Health Economics 2016; 17:

Christofides E., Dobson JA., Solomon M., Waters V., O'Doherty KC.
Heuristic decision-making about research participation in children with cystic fibrosis
Social Science & Medicine 2016; 162: 32 - 40

Grossoehme DH., Szczesniak RD., Mrug S., Dimitriou SM., Marshall A., McPhail GL.
Adolescents' Spirituality and Cystic Fibrosis Airway Clearance Treatment Adherence: Examining Mediators
Journal of Pediatric Psychology 2016; 41: 1022 - 1032

Hull J.
Lifestyle treatments in cystic fibrosis: The NHS should not pay
Paediatric Respiratory Reviews 2016; 20:

Kettle R.
Lifestyle treatments in cystic fibrosis: The NHS should pay
Paediatric Respiratory Reviews 2016; 20:

Mantzos M., Egan H.
Mindfulness Training May Enhance the Psychological Well-Being of People with Cystic Fibrosis
Mindfulness 2016; 7: 781 - 784

Milmansgruber H., Smrekur U., Rabanser B., Beck T., Eder J., Eilenhuber H.
Psychological resilience and intolerance of uncertainty in coping with cystic fibrosis
Journal of Cystic Fibrosis 2016; 15: 689 - 695

Oates GR., Schechter MS.
Socioeconomic status and health outcomes: cystic fibrosis as a model

Patrick JRD., da Fonseca MA., Kaste LM., Fadavi S., Shah N., Sroussi H.
Oral Health-related quality of life in pediatric patients with cystic fibrosis
Special Care in Dentistry 2016; 36: 187 - 193

Racul C., Toews M., Caulfield T.
Controversies with Kalydeco: Newspaper coverage in Canada and the United States of the cystic fibrosis "wonder drug"
Journal of Cystic Fibrosis 2016; 15: 624 - 629

Sarvas EW., Huebner CE., Scott JM., Aps JKM., Chi DL.
Dental utilization for Medicaid-enrolled children with cystic fibrosis
Special Care in Dentistry 2016; 36: 315 - 320

Smith BA., Georgiopoulos AM., Quittner AL.
Maintaining mental health and function for the long run in cystic fibrosis
Pediatric Pulmonology 2016; 51:

West NE., Mogayzel PJ.
Transitions in Health Care What Can We Learn from Our Experience with Cystic Fibrosis
Pediatric Clinics of North America 2016; 63: 887 –

Pulmonology

Unravelling the role of sphingolipids in cystic fibrosis lung disease
Chemistry and Physics of Lipids 2016; 200: 94 - 103


Wielputz MO., Eichinger M., Biederer J., Wege S., Stahl MA., Sommerburg O., Mall MA., Kauzor HU., Puderbach M. Imaging of Cystic Fibrosis Lung Disease and Clinical Interpretation Rofo-Fortschr. auf Dem Gebiet Der Rontgenstrahlen Und Der Der 2016; 188: 834 - 845

Screening


Britton LJ., Oates GR., Oster RA., Self ST., Troxler RB., Hoover WC., Gutierrez HH., Harris WT. Risk stratification model to detect early pulmonary disease in infants with cystic fibrosis diagnosed by newborn screening Pediatric Pulmonology 2016; 51: 1168 - 1176


Machogu E., Ren CL. Novel insights into the diagnostic and therapeutic challenges of the CFTR metabolic syndrome:CF screen positive indeterminate diagnosis Pediatric Pulmonology 2016; 51: 846 - 863


Therapy


Arora K., Naren AP.
Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function
Current Drug Targets 2016; 17: 1275 - 1281

Balfour-Lynn IM., Welch K.
Inhaled corticosteroids for cystic fibrosis
Cochrane Database of Systematic Reviews 2016; : 8:CD001915

Beekman JM.
Individualized medicine using intestinal responses to CFTR potentiators and correctors
Pediatric Pulmonology 2016; 51:

Bodewes FAJA., Verkade HJ., Wilschanski M.
Gastroenterological endpoints in drug trials for cystic fibrosis
Pediatric Pulmonology 2016; 51:

Bos AC., Tiddens HAWM., Minh KT., Heeres I., Overveer-Uijterliende JL., Kok AE., Andrinopoulou ER., Janssens HM.
Daily Observations of Nebuliser Use and Technique (DONUT) in children with cystic fibrosis
Journal of Cystic Fibrosis 2016; 15: 645 - 651

Brivio A., Conese M., Gambazza S., Biffi A., Tirelli AS., Rasso M., Foa M., Colombo C.
Pilot Randomized Controlled Trial Evaluating the Effect of Hypertonic Saline With and Without Hyaluronic Acid in Reducing Inflammation in Cystic Fibrosis

Carter SC., McKone EF.
Pharmacogenetics of cystic fibrosis treatment
Pharmacogenomics 2016; 17: 1453 - 1463

Chassagnon G., Hubert D., Fajac I., Burgeil PR., Revel MP.
Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor
European Respiratory Journal 2016; 48: 249 - 252

Dekkers JF., Van Mourik P., Vonk AM., Van der Ent K., Beekman JM.
Potentiator synergy in rectal organoids carrying S1251N, G551D, or F508del CFTR mutations

Dilokthornsakul P., Hansen RN., Campbell JD.
Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation
European Respiratory Journal 2016; 47: 1697 - 1705

El Khoury J., Habre S., Nasr M., Hakayem N.
Botulinum Neurotoxin A for Parotid Enlargement in Cystic Fibrosis: The First Case Report

Complementary and alternative medicine use in children with cystic fibrosis
Complementary Therapies in Clinical Practice 2016; 25: 68 - 74

Heubi JE., Schaeffer D., Ahrens RC., Sollo N., Strausbaugh S., Graff G., Jain R., Witte S., Forssmann K.
Safety and Efficacy of a Novel Microbial Lipase in Patients with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis: A Randomized Controlled Clinical Trial
Journal of Pediatrics 2016; 176: 156 - +

Hubert D., Bui S., Marguet C., Colomb-Jung V., Murriss-Espin M., Corvol H., Munck A.
New therapies for cystic fibrosis targeting the CFTR gene or the CFTR protein
Revue des Maladies Respiratoires 2016; 33: 658 - 665

Irons JY., Petocz P., Kenny DT., Chang AB.
Singing as an adjunct therapy for children and adults with cystic fibrosis
Cochrane Database of Systematic Reviews 2016; : 9:CD008036

Jordan CL., Noah TL., Henry MM.
Therapeutic challenges posed by critical drug-drug interactions in cystic fibrosis
Pediatric Pulmonology 2016; 51:

Laselva O., Molinski S., Casavola V., Bear CE.
The investigational Cystic Fibrosis drug Trimethylglycine directly modulates CFTR by stabilizing the first membrane-spanning domain
Biochemical Pharmacology 2016; 119: 85 - 92

McGarry ME., McColey SA.
Minorities Are Underrepresented in Clinical Trials of Pharmaceutical Agents for Cystic Fibrosis

Biomarkers for cystic fibrosis drug development
Journal of Cystic Fibrosis 2016; 15: 714 - 723

Noordhoek J., Galmans V., van der Ent K., Beekman JM.
Intestinal organoids and personalized medicine in cystic fibrosis: a successful patient-oriented research collaboration
Current Opinion in Pulmonary Medicine 2016; 22: 610 - 616

Schneider EK., Reyes-Ortega F., Wilson JW., Kotsimbos T., Keating D., Li J., Velkov T.
Development of HPLC and LC-MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO
Journal of Chromatography B-Analytical Technologies in the Biomedical 2016; 1038: 57 - 62

Sorbera LA., Tremosa L., Dulsat C.
Therapeutic targets for cystic fibrosis
Drugs of the Future 2016; 41: 367 - 374

Spielberg DR., Clancy JP.
Cystic Fibrosis and Its Management through Established and Emerging Therapies
Annual Review of Genomics and Human Genetics, Vol 17 2016; 17: 135 - 175

Suthoff ED., Bonafe M., Limone B., O’Callaghan L., Sawicki GS., Wagener JS.
Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis
Journal of Medical Economics 2016; 19: 845 - 851

VanDevanter DR., Heltshe SL., LiPuma JJ.
Potential for Therapeutic Benefit among Cystic Fibrosis Populations Excluded from Clinical Trials or Labeling of Marketed Therapies

Weckmann M., Schultheiss C., Hollaender A., Bobis L., Rupp J., Kopp MV.
Treatment with rhDNase in patients with cystic fibrosis alters in-vitro CHIT-1 activity of isolated leukocytes
Clinical and Experimental Immunology 2016; 185: 382 - 391
Yu B., Jiang Y., Jin LL., Ma TH., Yang H.
Role of Quercetin in Modulating Chloride Transport in the Intestine
*Frontiers in Physiology* 2016; 7: ArNo: 549

[Anonymous].
Cystic Fibrosis: recent Studies - new Drugs In June, new Data for Ivacaftor and Lumacaftor/Ivacaftor were presented at the Conference of the European Cystic Fibrosis Society
*Padiatrie Und Padiologie* 2016; 51: 186 - 187

**Transplantation**

Chaparro C., Keshavjee S.
Lung transplantation for cystic fibrosis: an update

Hayes D., Glanville AR., McGiffin D., Tobias JD., Tumin D.
Age-related survival disparity associated with lung transplantation in cystic fibrosis: An analysis of the registry of the International Society for Heart and Lung Transplantation
*Journal of Heart and Lung Transplantation* 2016; 35: 1108 - 1115

Hayes D., Tumin D., Kopp BT., Tobias JD., Sheikh SI., Kirkby SE.
Influence of graft ischemic time on survival in children with cystic fibrosis after lung transplantation
*Pediatric Pulmonology* 2016; 51: 908 - 913

Kimura N., Khan MS., Scheeter M., Rizwan R., Bryant R., Wells E., Towe C., Zafar F., Morales DLS.
Changing demographics and outcomes of lung transplantation recipients with cystic fibrosis
*Journal of Heart and Lung Transplantation* 2016; 35: 1237 - 1244

Krivchenia K., Hayes D., Tobias JD., Tumin D.
Long-term work participation among cystic fibrosis patients undergoing lung transplantation
*Journal of Cystic Fibrosis* 2016; 15: 846 - 849

Krivchenia K., Tumin D., Tobias JD., Hayes D.
Increased Mortality in Adult Cystic Fibrosis Patients with Medicaid Insurance Awaiting Lung Transplantation
*Lung* 2016; 194: 799 - 806

Naranjo ID., Charterina SA.
What can happen after lung transplantation and the importance of the time since transplantation: radiological review of post-transplantation complications
*Radiologia* 2016; 58: 257 - 267

Piazza M., Martucci G., Arcadipane A.
Postoperative pain management of liver transplantation in cystic fibrosis: Is it time to start US-guided neuraxial blocks?

Raghavan D., Gao A., Ahu C., Kaza V., Finklea J., Torres F., Jain R.
Lung transplantation and gender effects on survival of recipients with cystic fibrosis
*Journal of Heart and Lung Transplantation* 2016; 35: 1487 - 1496

Syed SA., Whelan FJ., Waddell B., Rabin HR., Parkins MD., Surette MG.
Reemergence of Lower-Airway Microbiota in Lung Transplant Patients with Cystic Fibrosis